

# ALPIC 2016

Advanced Learning on Plateles & Thrombosis International Course

March, 25-26, 2016

Kalavrita Canyon Hotel

KALAVRITA - GREECE

#### Organized by



Institute for the Study and Education  
on Thrombosis and Antithrombotic Therapy



Atherothrombosis Research Centre,  
University of Ioannina

#### Course Directors

Alexandros Tselepis  
Professor of Biochemistry-Clinical Chemistry  
Department of Chemistry, University of Ioannina

John Goudevenos  
Professor of Cardiology, School of Medicine,  
University of Ioannina

#### Under the auspices of:



European and Mediterranean League  
Against Thrombotic Diseases



Hellenic Cardiological Society

#### Endorsed by:



International Society  
on Thrombosis and Haemostasis

The course  
has been accredited  
with 12 CME credits  
by the  
Panhellenic Medical  
Association

[www.alpic2016.gr](http://www.alpic2016.gr)

**FINAL PROGRAMME**



**BRILIQUE™**  
ticagrelor

ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ: Κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 90 mg ticagrelόρη.  
Πριν από τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών Προϊόντος.

**AstraZeneca** 

Θεσσοκοπούλου 4 & Αστροναυτών, 151 25 Μαρούσι, Αθήνα  
Τηλ.: 210 6871500, Fax: 210 6859195 • Τηλ. παραγγελιών: 210 5596970-72, Fax: 210 5596973  
[www.astrazeneca.gr](http://www.astrazeneca.gr)

# DuoPlavin<sup>®</sup>

Clopidogrel 75mg/ASA 100mg

ΚΛΟΠΙΔΟΓΡΕΛΗ 75mg

ΑΣΟ 100mg



Συσκευασία των

**30 δισκίων**

# Plavix<sup>®</sup>

(clopidogrel hydrogen sulphate)  
75 mg and 300mg film-coated tablets

75 mg tabs

Συσκευασία των

**28 δισκίων**

Το μόνο  
auto-generic  
του Plavix<sup>®</sup>

# Clopidogrel Zentiva<sup>®</sup>

(clopidogrel hydrogen sulphate)  
75 mg film-coated tablets

Συσκευασία των

**28 δισκίων**



Sanofi-aventis A.E.B.E. Λεωφ. Συγγρού 348, Κτίριο Α', 176 74 Καλλιθέα, Τηλ.: 210 90 01 600, Fax: 210 92 49 342, [www.sanofi.gr](http://www.sanofi.gr)

Πριν από τη συνταγογράφηση συμβουλευθείτε τις Π.Χ.Π. που βρίσκονται στον ιστότοπο της εταιρείας [www.sanofi.gr](http://www.sanofi.gr).  
Για περισσότερες πληροφορίες απευθυνθείτε στο Τμήμα Ιατρικής Πληροφόρησης της Sanofi στο τηλέφωνο 210 9001600  
ή στην ηλεκτρονική διεύθυνση [medicalinformation.greece@sanofi.com](mailto:medicalinformation.greece@sanofi.com)

Welcome Message ..... 5

ALPIC Organizers & Committees ..... 6-7

General Information ..... 8-11

Scientific Program

    Friday, March 25<sup>th</sup>, 2016 ..... 12-17

    Saturday, March 26<sup>st</sup>, 2016 ..... 18-24

Index/ Invited Faculty ..... 25-31

Sponsors ..... 32

Dear Colleagues

We are pleased to welcome you to **ALPIC 2016** (Advanced Learning on Platelets & thrombosis International Course), the sixth international scientific event on Platelets and Thrombosis, taking place this year in Kalavrita, at Kalavrita Canyon Hotel, Peloponessos, Greece, on **March 25-26 2016**.

ALPIC 2016 is organized by the **Institute for the Study and Education on Thrombosis and Antithrombotic Therapy** as well as the **Atherothrombosis Research Centre of the University of Ioannina**, under the auspices of the **European and Mediterranean League Against Thrombotic Diseases (EMLTD)** and the **Hellenic Cardiological Society**. The Course is also endorsed by the **International Society on Thrombosis and Haemostasis (ISTH)**.

The Course aims to serve as a knowledge transfer forum for scientists in the current aspects of Platelet and Thrombosis research, ranging from the basic science to the clinical practice. The scientific program is designed to highlight the rapid development and ongoing evolution on the pathophysiology of Thrombosis along with discussion regarding all current advances in Antiplatelet and Anticoagulant therapy.

An internationally recognized panel of invited speakers will present state-of-the-art lectures on the above scientific fields and will create an excellent opportunity for all participants to stimulate an extended and very constructive discussion both inside and outside the lecture hall.

The dreamy setting with picturesque squares, stone-paved streets and cute little houses of Kalavrita will welcome ALPIC 2016. Kalavrita is a town, a province and a municipality in the East Central part of the prefecture of Achaia. The historic town of Kalavryta, one of the most exciting destinations of Peloponnese, will add to the scientific quality of the presentations, making this event a remarkable one for all participants. The Organizers will spare no efforts to ensure that ALPIC 2016 will be an exciting and enriching experience.

At this point we would like to extend our sincere thanks to all those who worked with dedication, putting together this attractive and comprehensive scientific program, namely the International Invited Faculty for its warm acceptance to participate in ALPIC 2016, the Local Scientific Committee, the International Scientific Advisory Board and our sponsors for their generous support. Last but not least, we extend our warm welcome and gratitude to all colleagues for joining us at this course and sharing our enthusiasm.

We welcome you and we wish you all enjoy ALPIC 2016 in the picturesque landscape offered by Kalavrita and its mountainous landscape.

With our best regards,

**John Goudevenos**

Professor of Cardiology,  
School of Medicine, University of Ioannina

**Alexandros Tselepis**

Professor of Biochemistry-Clinical Chemistry  
Department of Chemistry,  
University of Ioannina

### Organized by:

---



Institute for the Study and Education on Thrombosis and Antithrombotic Therapy

#### Executive Committee

President: **A. Tselepis**  
 Vice President: **G. Andrikopoulos**  
 Secretary Special: **M. Matsagkas**  
 Secretary General: **D. Richter**  
 Treasurer: **E. Vavarounakis**  
 Members: **S. Vasdekis**  
**K. Vemmos**  
**G. Gerotziafas**  
**S. Sourmelis**



Atherothrombosis Research Centre, University of Ioannina

### Under the auspices of:

---



European and Mediterranean League Against Thrombotic Diseases



Hellenic Cardiological Society

### Endorsed by:

---



International Society on Thrombosis and Haemostasis

### Course Directors:

---

#### **Alexandros Tselepis**

Professor of Biochemistry-Clinical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

#### **John Goudevenos**

Professor of Cardiology, School of Medicine, University of Ioannina, Ioannina, Greece

### Local Scientific Committee

Alexopoulos Dimitrios  
 Andrikopoulos George  
 Arnaoutoglou Eleni  
 Bompotis George  
 Chantanis Stelios  
 Davlouros Periklis  
 Draganigos Antonios  
 Filippatos Gerasimos  
 Fousas Stefanos  
 Giannopoulos Sotirios  
 Giannoukas Athanasios  
 Godevenos Dimitrios  
 Goumas George  
 Hahalis George  
 Kafkas Nikolaos  
 Kalantzi Loretta  
 Kanakakis John  
 Kanonidis Ioannis  
 Kanoupakis Manolis  
 Karanikis Pavlos  
 Katsouras Christos  
 Konstantinides Stavros  
 Korantzopoulos Panagiotis  
 Kyriazis Ioannis  
 Lefkou Elmina  
 Makridis Dimitrios  
 Matsagkas Miltiadis  
 Milionis Haralampos  
 Nikas Dimitrios  
 Nikas Nikos

Nikolaou Maria  
 Ntaios George  
 Papadopoulos Thomas  
 Pappas Konstantinos  
 Papatthasiou Athanasios  
 Patsilinakos Sotirios  
 Petrou Anastasios  
 Pipilis Athanasios  
 Pyrgakis Vlassis  
 Richter Dimitrios  
 Sianos Georgios  
 Sionis Dimitrios  
 Skalidis Manolis  
 Sourmelis Savvas-George  
 Stakos Dimitrios  
 Triantis George  
 Triposkiadis Filippos  
 Tsiara Stavroula  
 Tsolakis Ioannis  
 Tsoukatos Demokritos  
 Tzeis Stelios  
 Tzimas Petros  
 Vasdekis Spyros  
 Vasilikos Vassilios  
 Vavouranakis Emmanouil  
 Vemmos Konstantinos  
 Vlasserou Fotini  
 Voudris Vassilios  
 Ziakas Antonios

### International Scientific Advisory Board

Angiolillo Dominick (USA)  
 Badimon Lina (Spain)  
 Bonello Laurent (France)  
 Cattaneo Marco (Italy)  
 Douketis James (Canada)  
 Elalamy Ismail (France)  
 Ferreiro Jose Luis (Spain)  
 Gerotziafas Grigoris (France)  
 Gurbel Paul (USA)  
 Hall Alistair (UK)  
 Heptinstall Stan (UK)

Mallett Susan (UK)  
 Michelson Alan (USA)  
 Morrow David (USA)  
 Paganelli Franck (France)  
 Papageorgiou Chrysoula (France)  
 Patrono Carlo (Italy)  
 Price Matthew (USA)  
 Schaefer Katrin (Germany)  
 Spyropoulos Alex (USA)  
 Stafylas Panagiotis (Belgium)

## ■ DATE & VENUE

---

**ALPIC 2016** Course, will be held from **Friday, March 25<sup>th</sup>** to **Saturday, March 26<sup>th</sup> 2016** in **Kalavrita**, at **Kalavrita Canyon Hotel, Greece**. The Course commences with Registration on Friday, March 25<sup>th</sup> in the morning, and concludes on Saturday, March 26<sup>th</sup> 2016 at night.

## ■ COURSE VENUE

---

Kalavrita Canyon Hotel  
Ethnikis Antistaseos & Skaltsa, Kalavrita 250 01  
Tel.: (+30) 26920-22004, Fax.: (+30) 26920-24305  
[info@kalavritacanyon.gr](mailto:info@kalavritacanyon.gr), [www.kalavritacanyon.gr](http://www.kalavritacanyon.gr)

## ■ THE TOWN OF KALAVRITA

---

Kalavrita is a town, a province and a municipality in the East Central part of the prefecture of Achaea. It is located 77 km SE of Patras (1.5 h driving through magnificent and eye-catching nature) and 180 km West of Athens. Kalavrita is a popular destination and can be visited throughout the year. Some of the essential points of interest are the Vouraikos Canyon which can be approached through the "Odontotos" (a rare example of a fully functional cog railway, offering breath-taking view), the Cave of the Lakes (close to the village Kastria of the Municipality of Klitoria, where the natural beauty of the lakes and the stalactitic decor attracts a great number of visitors; a must-see for the lower of geology y, petrology, anthropology and paleontology), the historic monasteries as well as the beautiful mountainvillages of the region.

## ■ ACCOMMODATION

---

An adequate number of rooms has been reserved in hotels in **Kalavrita**.  
**TIP:** Do not leave your hotel arrangements too late. Requests will be honored on a first-come first-served space-available basis. For reservations, kindly contact the Administrative-Organizing Bureau, Conferre Ltd ([info@conferre.gr](mailto:info@conferre.gr)).



## REGISTRATIONS

---

Registration for the course is **free of charge**.

## SECRETARIAT OPERATING HOURS

---

Friday, March 25<sup>th</sup> 2016: 08.00 - 14.30 & 15.45 - 21:00  
Saturday, March 26<sup>th</sup> 2016: 09.00 - 14.00 & 16.00 - 21:00

## LANGUAGES

---

The official languages of the course are **Greek** and **English**. The English language may be used widely especially in the presentations of the speakers to encourage the interaction in all scientific sessions of the English-speaking faculty. There will be no interpretation from English to Greek language and viceversa.

## CREDITS

---

The course will be accredited with **12 CME credits** by the Hellenic Medical Society.

## PARTICIPANTS' BADGE

---

All participants, upon confirmation of their registration at the Secretariat, will be provided with a name badge that bears a unique barcode. It must be clearly understood that barcode badges must be scanned before entering AND after exiting the Lecture Hall. According to the National Organization of Medicines Regulation participation for atleast of 60% of the total duration of the scientific program must be secured and recorded!

### Notes:

- It is obligatory for all participants to wear their badges always during the Course.
- Barcode name badge already used for recording attendance cannot be replaced with a second badge (as duration of attendance will not be allocated properly).
- Name badges are also necessary for admittance to the Dinners and the Lunch and to be returned to the Secretariat for receiving the Certificate(s) of Attendance.
- Time slots for breaks will not be recorded.

### ■ CERTIFICATES OF ATTENDANCE

---

All registered participants are entitled to receive a Certificate of Attendance. The Certificate will be issued only upon display of participant badge, which will be issued by the course secretariat.

### ■ WEBSITE

---

The official course website <http://www.alpic2016.gr> will provide the participants with a wide range of information. Participants are kindly requested to visit the site regularly for all updates.

### ■ PPT PRESENTATIONS

---

All who have presentations are kindly requested to deliver their presentation(s) in PPT format to the technical support personnel **at least one (1) hour before the beginning of the Session** (in order to ensure on time they run smoothly and to be able of making any possible changes). *If the presentation is scheduled early in the morning, you are kindly requested to check your presentation with the technical support personnel the day before.*

### ■ EVALUATION FORM (mandatory)

---

All participants by the end of the Course are requested to complete and deliver to the Secretariat a relative Evaluation Form (anonymous) as feedback of their experience during the Course.

### ■ SOCIAL EVENTS

---

Along with the conference material, during the registration on 25<sup>th</sup> of March 2016, participants will find enclosed the coupons for their meals (on Friday 25/3/2016 & on Saturday 26/3/2016) included in their accommodation package.

Participants are kindly requested to present their badge for admittance to the above meals along with the coupon valid for 1 person. Due to the large number of participants, you are kindly requested by the Organizing Committee to respect the instructions about the distribution of participants to the different restaurants, where the meals will take place.

### ■ EXHIBITION

---

The course will be accompanied by a major exhibition where pharmaceutical and / or equipment / device industries will display relevant products and therapeutic developments. Pharmaceutical companies and medical publishers are invited to participate to the course and exhibition.

### ■ LIABILITY AND INSURANCE

---

The course Organizers cannot accept liability for personal accidents or loss or damage to private property of participants and accompanying persons. Participants should make their own arrangements with respect to health and travel insurance.

### ■ ORGANIZING - ADMINISTRATIVE BUREAU/ SECRETARIAT


---

**Conferre Ltd:** *"The Art of Bringing People Together"*  
St. Niarhou Avenue, GR 451 10 Ioannina, Greece  
Tel: +30 26510 68610, Fax: +30 26510 68611  
E-mail: [info@conferre.gr](mailto:info@conferre.gr), Website: [www.conferre.gr](http://www.conferre.gr)



# Liptruzet<sup>®</sup>

(ezetimibe and atorvastatin) tablets



Για περισσότερες συνταγογραφικές πληροφορίες συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος.



**MSD**

Κάτοχος της άδειας κυκλοφορίας:  
Merck Sharp & Dohme Ltd, Ηνωμένο Βασίλειο  
Τοπικός Αντιπρόσωπος στην Ελλάδα:

**MSD Α.Φ.Β.Ε.Ε.**

ΑΘΗΝΑ: Αγ. Δημητρίου 63, 174 56 Άλιμος,  
Τηλ.: 2109897300, [dpo\\_c\\_greece@merck.com](mailto:dpo_c_greece@merck.com)



Συν-προώθηση από την Εταιρεία:

**BIANEX Α.Ε. ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ**

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ:

ΑΘΗΝΑ: Οδός Τατσίου 146 71 Ν. Ερυθραία,  
Τηλ.: 210 8009111 • [mailbox@vianex.gr](mailto:mailbox@vianex.gr)

Friday, March 25<sup>th</sup>, 2016

**08.00-09.15 Registrations**

---

**09.15-09.30 Welcome addresses**

Vice Rector of the University of Ioannina  
**Thomas Bakas (Greece)**

ISTH Representatives  
**Marco Cattaneo (Italy)**  
Chairman Committee of Lectures and Awards

**James Douketis (Canada)**  
Chairman Committee of Guidelines and Guidance

President of the Hellenic Cardiological Society  
**Stefanos Fousas (Greece)**

President of ISETAT  
**Alexandros Tselepis (Greece)**

---

Friday, March 25<sup>th</sup>, 2016**09.30-11:00 Clinical Workshop: Cases receiving oral anticoagulants and presenting with acute coronary syndromes or bleeding**

Chairmen: **Manolis Skalidis (Greece),  
Dimitrios Sionis (Greece),  
George Triantis (Greece)**

**Case 1.** 63 year old man with history of TIAs. UGIB under DAPT and ACS requiring revascularization

**Case 2.** 58 year old man with NSTEMI. History of UGIB (due to aspirin?) and recurrence of UGIB after PCI

**Case 3.** Male with history of ?PAF presenting with ACS and 3 VD> PAF during procedure

**Case 4.** Active bleeding and ACS

**Case 5.** A patient with STEMI taking VKAs for mechanical cardiac valve

**Case 6.** Patient with cancer developing DVT

**Case 7.** Hemodialysis patient with atrial fibrillation

Cases presenters:

**John Goudevenos (Greece),  
Haralampos Milionis (Greece),  
Loreta Kalantzi (Greece),  
Athanasios Papathanasiou (Greece),  
Dimitrios Makridis (Greece)  
Nikas Dimitrios (Greece)**

Discussants:

**Nikolaos Kafkas (Greece),  
Panagiotis Korantzopoulos (Greece),  
Pavlos Karanikis (Greece),  
Konstantinos Pappas (Greece),  
Maria Nikolaou (Greece)**

Friday, March 25<sup>th</sup>, 2016

**11.00-11.30 Coffee Break**

**11.30-13.00 Distinguished Lectures**

Chairmen: **Alexandros Tselepis (Greece),  
Georgios Sianos (Greece)**

11.30-12.00 P2Y12 receptors: structure and function  
**Marco Cattaneo (Italy)**

12.00-12.30 Inhibited and uninhibited platelet deposition within a thrombus. Does it depend on the antiplatelet drug?  
**Paul Gurbel (USA)**

12.30-13.00 Antiplatelet treatment in ACS: the Greek experience  
**Dimitrios Alexopoulos (Greece)**

**13.00-14.30 Meet the Experts: DOACs in clinical practice**

Chairmen: **Alex Spyropoulos (USA),  
Filippos Triposkiadis (Greece)**

13.00-13.20 DOACs in specific patient populations (AF ablation, device implantation, cardioversion)  
**Panagiotis Korantzopoulos (Greece)**

13.20-13.40 DOACs in AF requiring PCI  
**John Goudevenos (Greece)**

13.40-14.00 AF: When to stop and restart DOACs in patients undergoing a planned surgical intervention?  
**Manolis Kanoupakis (Greece)**

14.00-14.20 When and how to measure the anticoagulant effect of DOACs?  
**Stavroula Tsiara (Greece)**

14.20-14.30 Panel discussion and implication for patient care

Friday, March 25<sup>th</sup>, 2016

## 14.30 -15.45 Break

**15.45-17.10 Round Table: Basic Research on Thrombosis**

Chairmen: **Dimitrios Stakos (Greece),  
Antonios Draganigos (Greece)**

**15.45-16.00 INVESTIGATION OF THE SELECTIVITY AND OPTIMAL CONDITIONS FOR EXPRESSION OF THE MAXIMAL ACTIVITY OF VORAPAXAR, *IN VITRO***

I.C. Moschonas<sup>1</sup>, S. Papadaki<sup>1</sup>, A.D. Tselepis<sup>1</sup>

<sup>1</sup>*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina*

**16.00-16.15 EXPLORING THE ANTITHROMBOTIC AND ANTIPLATELET EFFECT OF A NOVEL UREA ANALOGUE ON EXPERIMENTAL ARTERY THROMBOSIS, *IN VIVO***

S. Papadaki<sup>1</sup>, I. Moschonas<sup>1</sup>, M. Peroulis<sup>3</sup>, P. Tatsidou<sup>1</sup>,  
A. Sarantou<sup>2</sup>, C. Tellis<sup>1</sup>, G. Varvounis<sup>2</sup>, A. Tselepis<sup>1</sup>

<sup>1</sup>*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina*

<sup>2</sup>*Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece*

<sup>3</sup>*University Hospital of Ioannina, Ioannina, Greece*

**16.15-16.30 EXPLORING THE PLEIOTROPIC EFFECTS OF TICAGRELOR**

S. Sidiropoulou<sup>1</sup>, A.D. Tselepis<sup>1</sup>

<sup>1</sup>*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina*



Friday, March 25<sup>th</sup>, 2016

- 16.30-16.45 **PLATELET- NEUTROPHIL CROSSTALK IN THROMBOTIC DISORDERS**  
D. Stakos<sup>1</sup>  
*<sup>1</sup>School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece*
- 16.45-17.10 **Lecture**  
MRP-4 and platelets  
**Demokritos Tsoukatos (Greece)**
- 17.10-19.20 Round Table: Antithrombotic therapy after ACS-PCI**  
Chairmen: Stefanos Fousas (Greece),  
**Emmanouil Vavouranakis (Greece)**
- 17.10-17.30 DAPT with aspirin and clopidogrel after ACS-PCI. Should we continue beyond 12 months?  
**John Kanakakis (Greece)**
- 17.30-17.50 Benefits and risks of extended DAPT with aspirin and clopidogrel after coronary stenting: Does the type of stent influence the clinical outcome?  
**Vassilios Voudris (Greece)**
- 17.50-18.10 The fate of IIb/IIIa after cangrelor  
**Sotiris Patsilinakos (Greece)**
- 18.10-18.30 Deciding about prolonged ticagrelor therapy for secondary prevention: an ongoing dilemma  
**Periklis Davlouros (Greece)**
- 18.30-18.50 Efficacy of cilostazol in ACS patients undergoing PCI  
**Paul Gurbel (USA)**

Friday, March 25<sup>th</sup>, 2016

18.50-19.10 Which is the best anticoagulant strategy during primary PCI for STEMI?  
**George Hahalis (Greece)**

19.10-19.20 Panel discussion and implication for patient care

---

**19.20-21.00 Meet the Experts: Antiplatelets in special situations**  
Chairmen: **Konstantinos Vemmos (Greece),**  
**George Bompotis (Greece)**

19.20-19.40 Antithrombotic therapy in the elderly: Consensus statement of the ESC Working Group on Thrombosis  
**Marco Cattaneo (Italy)**

19.40-20.00 Carotid and Peripheral arterial disease  
**Dimitrios Nikas (Greece)**

20.00-20.20 Patients presenting with acute stroke while on DOACs  
**Konstantinos Vemmos (Greece)**

20.20-20.40 TAVI, PFO, CABG  
**Emmanouil Vavouranakis (Greece)**

20.40-21.00 PAR-1 antagonist: In which patients?  
**Alexandros Tselepis (Greece)**

---

**21.00 Dinner**

---

Saturday, March 26<sup>st</sup>, 2016**09.00-10:30 Round table: Meet the experts. Antithrombotics:  
To Bridge or not to Bridge**

Chairmen: **Vlassis Pyrgakis (Greece),  
Eleni Arnaoutoglou (Greece)**

**Case 1.** Patient with mechanical cardiac valve undergoing Pacemaker implantation

**Case 2.** Patient under combination DAPT and warfarin treatment undergoing major noncardiac surgery

**Case 3.** 75 years old female with chronic AF under anticoagulants and GI bleeding

**Case 4.** 75 years old with known PCI prostate cancer. Now ACS 2VD PCI restenosis. DAPT (Aspirin+Ticagrelor) and slow AF within 3 days of PCI

**Case 5.** A case of paroxysmal AF detected in Holter

**Case 6.** A case of TAVI and AF

**Case 7.** 70 years old woman with AF treated with NOAC presented with a femur fracture

Cases presenters:

**John Goudevenos (Greece), Stelios Tzeis (Greece),  
Athanasios Pipilis (Greece), Antonios Ziakas (Greece) ,  
Panagiotis Korantzopoulos (Greece)**

Discussants:

**James Douketis (Canada), Alex Spyropoulos (USA),  
Dimitrios Godevenos (Greece),  
Anastasios Petrou (Greece), Petros Tzimas (Greece)**

**Saturday, March 26<sup>st</sup>, 2016****10.30-11.00 Coffee Break****11.00-12.00 Distinguished Lectures**

Chairmen: **Miltiadis Matsagkas (Greece),  
Ioannis Tsolakis (Greece)**

11.00-11.30 Perioperative Bridging Anticoagulation in AF Patients  
**James Douketis (Canada)**

11.30 -12.00 Management of anticoagulants in the periprocedural period  
for patients with cancer  
**Alex Spyropoulos (USA)**

**12.00-14.00 Round Table: Antithrombotic therapy in specific  
populations**

Chairmen: **Ioannis Kanonidis (Greece),  
Gerasimos Filippatos (Greece)**

12.00-12.15 Current antithrombotic treatment strategy in patients with  
diabetes mellitus  
**Athanasios Pipilis (Greece)**

12.15-12.30 Long-term risk-benefit effect of low-dose aspirin in primary  
prevention  
**Christos Katsouras (Greece)**

12.30-12.45 Oral anticoagulants in AF patients with a malignancy  
**Haralampos Milionis (Greece)**

12.45-13.00 DOACs in ACS  
**Thomas Papadopoulos (Greece)**

13.00-13.15 DOACs in patients with Heart failure  
**Gerasimos Filippatos (Greece)**

Saturday, March 26<sup>st</sup>, 2016

- 13.15-13.30 DOACs for VTE. Where have we come from and where we are going?  
**Miltiadis Matsagkas (Greece)**
- 13.30-13.45 Thromboprophylaxis after elective major orthopedic surgery  
**Savvas Sourmelis (Greece)**
- 13.45-14.00 Discussion

**14.00-15.45 Break**

**15.45-17.05 Round Table: Clinical Research on Thrombosis**  
Chairmen: **Sotirios Giannopoulos (Greece),**  
**Stelios Chantanis (Greece)**

- 15.45-16.00 **HIGH ON-TREATMENT PLATELET REACTIVITY IN ISCHEMIC STROKE**  
A. Fiolaki<sup>1</sup>, Ah. Katsanos<sup>1</sup>, S. Papadaki<sup>2</sup>, I. Moschonas<sup>2</sup>, AP. Kyritsis<sup>1</sup>, A. Tselepis<sup>2</sup>, S. Giannopoulos<sup>1</sup>  
<sup>1</sup>*Department of Neurology, School of Health Sciences, University of Ioannina, Ioannina, Greece*  
<sup>2</sup>*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina*
- 16.00-16.15 **AGAINST THE DEFINITION OF EMBOLIC STROKE OF UNDETERMINED SOURCE: THE MISSING LINKS**  
Ah. Katsanos<sup>1</sup>, A. Fiolaki<sup>1</sup>, K. Pappas<sup>2</sup>, G. Tsvigoulis<sup>1</sup>, J. Goudevenos<sup>2</sup>, S. Giannopoulos<sup>1</sup>  
<sup>1</sup>*Department of Neurology, School of Health Sciences, University of Ioannina, Ioannina, Greece*  
<sup>1</sup>*Department of Cardiology, School of Health Sciences, University of Ioannina, Ioannina, Greece*

Saturday, March 26<sup>st</sup>, 2016

16.15-16.30 **ANTICOAGULATION THERAPY IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE IN GREECE: RESULTS FROM CHALLENGE REGISTRY**

G. Giannakoulas<sup>1</sup>, K. Vasiliadis<sup>2</sup>, A. Frogoudaki<sup>3</sup>, A. Tzifa<sup>4</sup>, C. Ntellos<sup>5</sup>, S. Brill<sup>6</sup>, A. Manginas<sup>7</sup>, M. Papaphylactou<sup>8</sup>, D. Parcharidou<sup>1,9</sup>, N. Kampourides<sup>10</sup>, G. Krasopoulos<sup>11</sup>, A. Douras<sup>12</sup>, G. Papadopoulos<sup>13</sup>, P. Davlourous<sup>14</sup>, A. Chamaidi<sup>15</sup>, A. Vlahos<sup>16</sup>, A. Pitsis<sup>11</sup>, D. Ntiloudi<sup>1</sup>, F. Mitropoulos<sup>8</sup>, I. Vlaseros<sup>17</sup>, H. Karvounis<sup>1</sup>, G. Parcharidis<sup>9</sup>, S. Foussas<sup>17</sup>, C. Tsioufis<sup>17</sup>, S Rammos<sup>8</sup>

<sup>1</sup>*Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece*

<sup>2</sup>*Department of Cardiology, G. Papanikolaou Hospital, Exohi, Thessaloniki, Greece*

<sup>3</sup>*Department of Cardiology, Attikon University Hospital, Athens, Greece*

<sup>4</sup>*Department of Congenital Heart Disease, Mitera Children's Hospital, Athens, Greece*

<sup>5</sup>*Department of Cardiology, Tzaneio General Hospital of Piraeus, Athens, Greece*

<sup>6</sup>*Department of Cardiology, Ippokrateion University Hospital, Athens, Greece*

<sup>7</sup>*Department of Cardiology, Mediterraneo Hospital, Athens, Greece*

<sup>8</sup>*Department of Pediatric and Congenital Cardiac Surgery, Onassis Cardiac Surgery Centre, Athens, Greece*

<sup>9</sup>*Department of Cardiology, Interbalkan Hospital, Thessaloniki, Greece*

<sup>10</sup>*Department of Cardiology, General Hospital of Kavala, Kavala, Greece*

<sup>11</sup>*Department of Cardiology, Saint Luke's Clinic, Thessaloniki, Greece*

Saturday, March 26<sup>st</sup>, 2016

<sup>12</sup>Department of Cardiology, Achillopouleio General Hospital, Volos, Greece

<sup>13</sup>Department of Cardiology, General Children's Hospital "Pan. & Aglaia Kyriakou", Athens, Greece

<sup>14</sup>Department of Cardiology, University Hospital of Patra, Patra, Greece

<sup>15</sup>Department of Cardiology, University Hospital of Larisa, Larisa, Thessaloniki, Greece

<sup>16</sup>Department of Pediatric Cardiology, University Hospital of Ioannina, Ioannina, Greece

<sup>17</sup>Hellenic Cardiological Society

16.30-16.45 **DABIGATRAN PLASMA LEVELS, APTT AND THROMBOELASTOGRAPHY IN PATIENTS WITH AF: HOW MANY PATIENTS COULD THEORETICALLY UNDERGO A SURGICAL PROCEDURE EARLY-ON?**

A. Pipilis<sup>1</sup>, S. Makrygiannis<sup>1</sup>, G. Anagnostou<sup>2</sup>, S. Kaliambakos<sup>1</sup>, G. Tsakonas<sup>1</sup>, N. Sourlas<sup>1</sup>, P. Mallios<sup>1</sup>, T. Kostelidou<sup>2</sup>

<sup>1</sup>1<sup>st</sup> Cardiac department, Hygeia Hospital, Athens, Greece

<sup>2</sup>Haematology Anticoagulation department, Hygeia Hospital, Athens, Greece

16.45-17.05 **Lecture**

The evolution of clinical trials from the 20<sup>th</sup> to the 21<sup>st</sup> century  
**Nikos Nikas (Greece)**

Saturday, March 26<sup>st</sup>, 2016**17.05-17.30 The Management of Risk Factors for Atherothrombosis in the Primary Care practice. The Greek experience**

Introduction

**Alexandros Tselepis (Greece)**

Project description, aim, methodology

**Fotini Vlasserou (Greece)**

Presentation of results

**George Andrikopoulos (Greece)****17.30-18.00 Coffee Break****18.00 -20.00 Round Table: DOACs and real-world data: What have we learned that the RCTs have not told us?**Chairmen: **John Goudevenos (Greece),  
Spyros Vasdekis (Greece)**

18.00-18.20 Individualizing oral anticoagulant therapy for stroke prevention in AF. What factors are really important?  
**George Andrikopoulos (Greece)**

18.20-18.40 Eligibility for drugs in patients with AF in daily practice  
**John Goudevenos (Greece)**

18.40-19.00 Efficacy, safety and mortality in RWD vs RCTs  
**Dimitri Richter (Greece)**

19.00-19.20 Ensuring adherence to prescribed oral anticoagulant intake  
**George Goumas (Greece)**

19.20-19.40 How to deal with dosing errors?  
**Stelios Tzeis (Greece)**

19.40-20.00 Acute Stroke  
**George Ntaios (Greece)**



**Saturday, March 26<sup>st</sup>, 2016**

**20.00 -21.00 Round Table: Meet the experts. Management of bleeding in patients on DOACs**

Chairmen: **Athanasios Giannoukas (Greece),  
Vassilios Vasilikos (Greece)**

20.00 -20.20 What recent guidelines tell us?  
**Dimitris Richter (Greece)**

20.20 -20.40 Use of PCC, aPCC, rFVIIa  
**Elmina Lefkou (Greece)**

20.40 -21.00 Specific antidotes in DOACs reversal. How will this affect patient management?  
**Alexandros Tselepis (Greece)**

---

**21.00 Dinner**

---

<b>Alexopoulos Dimitrios</b>	Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece
<b>Andrikopoulos George</b>	Cardiologist, Director, Department of Cardiology, "Henry Dunant" Hospital of Athens, Athens, Greece
<b>Arnautoglou Eleni</b>	Associate Professor of Anaesthesiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
<b>Bompotis George</b>	Cardiologist, Director, Department of Cardiology, "Papageorgiou" General Hospital of Thessaloniki, Thessaloniki, Greece
<b>Cattaneo Marco</b>	Professor of Internal Medicine, Department of Medicine, Surgery and Dentist Science. University of Milan, Director, 3 <sup>rd</sup> Unit of Medicine, "San Paolo" Hospital, Milan, Italy
<b>Chantanis Stelios</b>	Director, Cardiology Department, "Tzaneio" General Hospital of Piraeus, Piraeus, Greece
<b>Davlouros Periklis</b>	Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece
<b>Douketis James</b>	Professor of Internal Medicine, Division of Hematology and Thromboembolism, Department of Medicine, University of Toronto, Toronto, Canada
<b>Draganigos Antonios</b>	Director, Department of Cardiology, General Hospital of Corfu, Corfu, Greece

- Filippatos Gerasimos** MD, FESC, FHFA, Professor of Cardiology, University of Athens, Head of Heart Failure Unit, Attikon University Hospital, Athens, Greece
- Fousas Stefanos** Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Athens, Director, Department of Cardiology, "Tzaneio" General Hospital of Piraeus, President, Hellenic Cardiological Society, Athens, Greece
- Giannopoulos Sotirios** Associate Professor of Neurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- Giannoukas Athanasios** Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
- Godevenos Dimitrios** Surgeon, Department of Surgery, University Hospital of Ioannina, Ioannina, Greece
- Goudevenos John** Professor of Cardiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Goumas George** Assistant Director, Department of Cardiology, Euroclinic of Athens, Athens, President of the Working Group of Prevention and Epidemiology of the Hellenic Society of Cardiology, Athens, Greece
- Gurbel Paul** Director, Sinai Center for Thrombosis Research Sinai, Hospital of Baltimore Associate Professor of Medicine Johns Hopkins University School of Medicine, Baltimore, USA

<b>Hahalis George</b>	Associate Professor of Cardiology, School of Medicine, University of Patras, Patras, Greece
<b>Kafkas Nikolaos</b>	Director, Cardiology Department, General Hospital of Attica KAT, Kēfissia, Attica, Greece
<b>Kalantzi Loreta</b>	Cardiologist, Ioannina, Greece
<b>Kanakakis John</b>	Director, Catheteriazon Laboratory, Department of Clinical Therapeutics, "Alexandra" General Hospital of Athens, Athens, Greece
<b>Kanonidis Ioannis</b>	Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
<b>Kanoupakis Manolis</b>	Director, Cardiology Department, University Hospital of Heraklion
<b>Karanikis Pavlos</b>	Consultant, Cardiology Department, "Hatzikosta" General Hospital of Ioannina, Ioannina, Greece
<b>Katsouras Christos</b>	Associate Professor of Cardiology, School of Medicine, University of Ioannina, Ioannina, Greece
<b>Korantzopoulos Panagiotis</b>	Assistant Professor of Cardiology, School of Medicine, University of Ioannina, Ioannina, Greece
<b>Lefkou Elmina</b>	Consultant Haematologist, Specialised in Haemostasis & Thrombosis, Obstetric Haematology, Antiphospholipid Syndrome, Thessaloniki, Greece

<b>Makridis Dimitrios</b>	Nephrologist, Consultant, Nephrologist Department, General Hospital of Ptolemaida Mpodosakeio, Ptolemaida, Greece
<b>Matsagkas Miltiadis</b>	Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
<b>Milionis Haralampos</b>	Professor of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
<b>Nikas Dimitrios</b>	MD, PhD, FESC Consultant Interventional Cardiologist 1 <sup>st</sup> Cardiology Department, Ioannina University Hospital Ioannina, Greece
<b>Nikas Nikos</b>	Medical Affairs Manager Cardiovascular at AstraZeneca Pharmaceuticals, Athens
<b>Nikolaou Maria</b>	Consultant, Cardiology Department, "Sismanoglio-A. Fleming" General Hospital of Athens, Athens, Greece
<b>Ntaios George</b>	Assistant Professor of Medicine, Department of Medicine & Research Laboratory of Internal Medicine, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece
<b>Papadopoulos Thomas</b>	MD, FSCAI, FACC, Interventional Cardiologist, Thessaloniki, Greece
<b>Papathanasiou Athanasios</b>	Cardiologist-Intensive Care Physician, Intensive Care Unit, University General Hospital of Ioannina, Ioannina, Greece
<b>Pappas Konstantinos</b>	Cardiologist, Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece

- Patsilidakos Sotirios** Director, Department of Cardiology, General Hospital of Athens «Konstadopouleio», Athens, Greece
- Petrou Anastasios** Assistant Professor of Anaesthesia, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- Pipilis Athanasios** Cardiologist, Director, 1<sup>st</sup> Department of Cardiology, "Hygeia" Diagnostic and Therapeutic Centre of Athens, Athens, Greece
- Pyrgakis Vlassis** Director, Department of Cardiology, "G. Gennimatas" General State Hospital of Athens, Athens, Greece
- Richter Dimitrios** Director, Department of Cardiology, Euroclinic of Athens, Athens, Greece
- Sianos Georgios** Assistant Professor of Cardiology, AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece
- Sionis Dimitrios** Cardiologist, Director, Catheterization Unit of Interventional Cardiology, "Sismanoglio-A. Fleming" General Hospital of Athens, Athens, Greece
- Skalidis Manolis** Assistant Professor of Cardiology, University of Heraklion, Heraklion, Greece
- Sourmelis Savvas- George** Orthopaedic Surgeon, 2<sup>nd</sup> Department of Orthopaedics, "Hygeia" Diagnostic and Therapeutic Centre of Athens, Athens, Greece

- Spyropoulos Alex** Director, Anticoagulation and Clinical Thrombosis Services, North Shore-LIJ Health System, Lenox Hill Hospital, Professor of Medicine, Hofstra-North Shore LIJ School of Medicine, Hofstra University, New York, USA
- Stakos Dimitrios** Assistant Professor of Cardiology, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
- Triantis George** Interventional cardiologist  
Catheterization and laboratory, "1<sup>st</sup> IKA" Hospital of Athens, Athens, Greece
- Trioskiadis Filippos** Professor of Cardiology, Director, Department of Cardiology, University Hospital of Larissa, Larissa, Greece
- Tselepis Alexandros** Professor of Biochemistry-Clinical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece
- Tsiara Stavroula** Associate Professor of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
- Tsolakis Ioannis** Professor of Vascular Surgery, School of Medicine, University of Patras, Patras, Greece
- Tsoukatos Demokritos** Associate Professor of Biological Chemistry, School of Medicine, University of Ioannina, Ioannina, Greece
- Tzeis Stelios** Cardiologist, Deputy Director, Department of Electrophysiology and Pacing, "Henri Dunant" Hospital Center of Athens, Athens, Greece
- Tzimas Petros** Assistant Professor in Anaesthesiology, School of Medicine, University of Ioannina, Ioannina, Greece

- Vasdekis Spyros** Associate Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece
- Vasilikos Vassilios** Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Vavouranakis Emmanouil** Assistant Professor of Cardiology, School of Medicine, University of Athens, Athens, Greece
- Vemmos Konstantinos** Stroke Internist, Consultant, Hellenic Cardiovascular Research Society, Athens, Greece
- Vlasserou Fotini** Medical Director, Vianex SA
- Voudris Vassilios** Cardiologist, Director, 2<sup>nd</sup> Division of Interventional Cardiology, Chairman, Department of Cardiology, "Onassis" Cardiac Surgery Center of Athens, Athens, Greece
- Ziakas Antonios** Assistant Professor of Cardiology, AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece



## SPONSORS

**ALPIC 2016**

The Organizers wish to thank the following pharmaceutical and / or equipment / device companies for their support in the accomplishment of the course:

### Major Sponsors

AstraZeneca 

 Bayer &  

  
SANOFI

 MSD & 

### Sponsors

  
**LIBYTEC**<sup>®</sup>  
ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.

  
Φ Α Ρ Μ Α Σ Ε Ρ Β

  
**UNI-PHARMA**

**ΕΠΡΩΝΥΜΟ  
ΕΛΛΗΝΙΚΟ  
ΦΑΡΜΑΚΟ**

# Clovelen®

Κλοπιδογρέλη

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Clovelen® 75 mg επικαλυμμένα με λεπτό υμένιο δισκία. **ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 75mg clopidogrel (κλοπιδογρέλης), ως besilate. Έκδοχα: κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 2.6mg μονοϋδρικής λακτόζης.

*Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.*



**ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ**  
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής, Τηλ.: 210 6039326-9, Fax: 210 6039300  
**ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ**  
Σεβαστείας 11, 115 28 Αθήνα, Τηλ.: 210 7488711, Fax: 210 7488731  
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη, Τηλ.: 2310 459920-1, Fax: 2310 459269

A hand holding a red heart, symbolizing health and care. The hand is wearing a yellow wristband labeled 'LDL' and a red wristband labeled 'HDL'. A red arrow points to the top of the heart.

# ΠΙΤΑΒΑ®

πιταβαστατίνη

CONVEY 22 ΠΙΤΑ 01/2016

Για συνταγογραφικές πληροφορίες απευθυνθείτε στην εταιρεία **ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ ΑΕΒΕ**



Δυνάμει σχετικής άδειας από την RECORDATI Ireland, Ltd Ringaskiddy, Ireland, την KOWA COMPANY LTD, και την NISSANCHEMICAL INDUSTRIES LTD




**ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε.**

15ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας, 14564 Κηφισιά τ 210 6294600 f 210 6294610

Γραφείο Θεσσαλονίκης: Αδριανουπόλεως 24, 551 33 Καψαριά, Θεσσαλονίκη τ 2310 480160

Για παραγγελίες: τ 210 6294629 f 210 6294630 e-mail [orders@lilly.gr](mailto:orders@lilly.gr) [www.lilly.gr](http://www.lilly.gr)



# Xarelto®

rivaroxaban

## Το πιο συχνά συνταγογραφούμενο νεότερο από του στόματος αντιπηκτικό παγκοσμίως<sup>1</sup>



**Bayer**

Κάτοχος της άδειας κυκλοφορίας:  
Bayer Pharma AG, 13342 Berlin, Γερμανία  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς ABEE,  
Σωρού 18-20, 151 25 Μαρούσι,  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Κύπρο: Novagem Ltd,  
Τηλ:00357 22483858

Τμήμα Επιστημονικής Ενημέρωσης  
Τηλ: +30 210 6187742, Fax: +30 210 6187522  
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπτρώθησης  
για τα 15 & 20mg



**ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ**  
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,  
Τηλ: 210 6039326 - 9, Fax: 210 6039300  
**ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ**  
Σεβαστείας 11, 115 28 Αθήνα,  
Τηλ: 210 7488711, Fax: 210 7488731  
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,  
Τηλ: 2310 459920 - 1, Fax: 2310 459269

LGRI.MKT.GM.02.2016.0523

### Βιβλιογραφικές αναφορές

1. Βάση Δεδομένων IMS Health MIDAS: Μηγισίες Πωλήσεις από Οκτώβριο 2008 ως Ιούνιο 2015

Πριν τη συνταγογράφηση για κάθε ένδειξη συμβουλευθείτε την αντίστοιχη Περιλήψη των Χαρακτηριστικών του Προϊόντος που διατίθεται στο εκθετήριο

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Ανοφφέρετε  
ΟΛΕΣ τις αναπλάσιμες ενέσεις για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»